

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Malin Life Sciences Holdings Ltd</u> (Last) (First) (Middle) <u>2 HARBOUR SQUARE, CROFTON ROAD</u> (Street) <u>DUN LAOGHAIRE, L2 CO., DUBLIN</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Novan, Inc. [NOVN]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>06/28/2019</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/28/2019		S		17,800	D	\$2.69 ⁽¹⁾	2,605,685	I	See Footnote ⁽²⁾
Common Stock	07/01/2019		S		913	D	\$2.74 ⁽³⁾	2,604,772	I	See Footnote ⁽²⁾
Common Stock	07/02/2019		S		6,287	D	\$2.75 ⁽⁴⁾	2,598,485	I	See Footnote ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* <u>Malin Life Sciences Holdings Ltd</u> (Last) (First) (Middle) <u>2 HARBOUR SQUARE, CROFTON ROAD</u> (Street) <u>DUN LAOGHAIRE, CO., L2 DUBLIN</u> (City) (State) (Zip)

1. Name and Address of Reporting Person*		
Malin Corp plc		
(Last)	(First)	(Middle)
2 HARBOUR SQUARE, CROFTON ROAD		
(Street)		
DUN LAOGHAIRE, CO., L2 DUBLIN		
(City)	(State)	(Zip)

Explanation of Responses:

1. The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$2.65 to \$2.83, inclusive. The reporting persons undertake to provide to Novan, Inc., any holder of Novan, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4.
2. Malin Life Sciences Holdings Ltd, the record holder of the shares, is a wholly owned subsidiary of Malin Corporation plc. Malin Corporation plc may be deemed to beneficially own the shares and may be deemed to share voting and dispositive power over these shares.
3. The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$2.73 to \$2.75, inclusive. The reporting persons undertake to provide to Novan, Inc., any holder of Novan, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
4. The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$2.75 to \$2.80, inclusive. The reporting persons undertake to provide to Novan, Inc., any holder of Novan, Inc. stock or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.

[Malin Life Sciences Holdings Ltd, By: /s/ Pat Jennings, 07/02/2019](#)
[Attorney-in-Fact](#)

[Malin Corporation plc, By: /s/ Pat Jennings, Attorney-in-Fact 07/02/2019](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.